Bilici M, et al. – The feasibility, efficacy, and safety of transcatheter closure of patent ductus arteriosus (PDA) with the Occlutech duct occluder (ODO) were examined in children. Outcomes approved that the Occlutech PDA occluder device was safe and effective in the closure of PDA.

• The clinical records of 71 patients who underwent percutaneous closure of PDA with an ODO between September 2014 and August 2016 were reviewed.
• During the study period (September 2014–August 2016), the Occlutech duct occluder was applied to 71 patients.
• 42 of the patients were female and 29 male.
• The median age was 20.5 months (range, 6–194 months) and median weight was 16 kg (range, 6–68 kg).
• Based on the Krichenko classification, the PDA was classified as type A in 54 patients (76.1%), type E in 14 (19.7%), type C in 2 (2.8%) and type B in 1 (1.4%).
• A standard ODO device was used for the transcatheter closure procedure in 66 patients and the long–shank ODO device in 5.
• In the echocardiographic measurement of PDA, the median smallest diameter was 2.7 mm (range, 1.5–7.0 mm), and in the angiographic measurement, the median smallest diameter was 2.5 mm (range, 1.5–6.5 mm).
• 71 patients underwent successful PDA closure with the ODO.
• Angiography following the procedure showed complete closure in 47 patients (66.2%), mild residual shunt in 13 patients (18.3%) and a trivial shunt in 11 patients (15.5%).
• Color flow Doppler echocardiogpaphy at 24 h post–implantation displayed that complete closure was achieved in 65 patients (91.5%), and 6 patients (8.5%) had mild residual shunt.
• At 30 days of follow–up, all patients (100%) had complete closure.